SARS-CoV-2 RBD ELISA Kit

COVID-19 disease is a respiratory illness caused by a novel coronavirus called systemic acute respiratory syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 belongs to the family of β-coronavirus. Its genome is about 30 kb long and shares about 80% of genome identity with SARS-CoV. The 3’ proximal terminal consists of 4 structural proteins: Spike (S), Membrane (M), Envelope (E), and Nucleocapsid (N). The S protein is a homo-trimeric, class I fusion, transmembrane glycoprotein. It promotes attachment, fusion, and entry of the virus into the host cells. The protein consists of two functional subunits, S1 and S2. The S1 subunit contains the N-terminal domain (NTD) and the C-terminal domain (CTD). The C-terminal domain consists of the receptor-binding domain (RBD) that binds and fuses to the angiotensin-converting enzyme 2 (ACE2) receptor located on the host cells and thus enables entry of the virus into the host. Due to its critical role in viral entry into the host cell, the RBD protein could serve as an efficient target antigen for the development of vaccines. BioVision’s SARS-CoV-2 RBD ELISA Kit is designed to quantitatively measure the amount of RBD protein in bronchoalveolar lavage fluid and nasopharyngeal swab samples. The assay is based on the Sandwich ELISA principle. Test samples, Standards, and Detection A solution are added to the wells pre-coated with the RBD antibody and then washed with Wash Buffer. The Detection B solution is added and any unattached conjugates are washed off using Wash Buffer. The enzymatic reaction is detected by the addition of TMB-substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the concentration of RBD in the sample or standard.